Dicerna Pharmaceuticals DRNA announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Sell-side analysts are expecting Dicerna's loss per share to be near 42 cents on sales of $1.78 million.
In the same quarter last year, Dicerna Pharmaceuticals reported a loss per share of 86 cents on sales of $252,000. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.38 | -0.65 | -0.69 | -0.6 |
| EPS Actual | -0.3 | -0.9 | -0.92 | -0.86 |
Stock Performance
Over the last 52-week period, shares are up 291.11 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release. Analysts have adjusted their estimates higher for EPS and revenues over the past 90 days. The average rating by analysts on Dicerna Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
